Dr. Tripathy on Maintenance Therapy in Breast Cancer

Video

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses maintenance therapy for patients with breast cancer.

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses maintenance therapy for patients with breast cancer.

Maintenance therapy is a difficult topic, Tripathy admits, many trials have looked at chemotherapy, hormonal, or targeted agents, and have demonstrated varying effects. Generally, it is understood that maintenance therapy may delay progression slightly. Many trials have not shown a survival advantage.

Some maintenance therapies are more conducive to a better quality of life, such as hormonal therapy or HER2-targeted therapy. The paradigm has shifted towards evaluating maintenance therapy in specific cases.

Part of the "art of oncology," Tripathy says, lies with when to use maintenance therapy, using common sense and data.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD